Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis

Original data analysis of the ketamine therapy provider landscape across all 50 states and DC, compiled from the Spravato REMS registry and ASKP member directory.

Data compiled and analyzed by DrugsRegistry.com · Published April 16, 2026 · Licensed under CC BY 4.0

Key Findings

As of April 2026, 3,606 ketamine therapy providers operate across 51 states and the District of Columbia in the United States. Of these, 3,302 (91.6%) are Spravato REMS-certified treatment centers registered with the FDA, and 419 (11.6%) are members of the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). California leads in total providers (336), while Nebraska has the highest per-capita density at 27.5 providers per million residents.

Contents

  1. Data Sources and Methodology
  2. National Overview
  3. Providers by State
  4. Clinic Density Per Capita
  5. Top Cities
  6. Provider Specialties
  7. Data Source Breakdown
  8. How to Cite

1. Data Sources and Methodology

This analysis draws on two primary data sources:

  1. Spravato REMS Registry — The FDA-mandated Risk Evaluation and Mitigation Strategy registry of healthcare facilities certified to administer Spravato (esketamine) nasal spray. This registry is maintained by Janssen Pharmaceuticals and the FDA. It contains 3,302 certified treatment centers.
  2. ASKP Member Directory — The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP) maintains a directory of its member clinics. This directory contains 419 member practices.

Records were cross-referenced using provider name, address, and NPI (National Provider Identifier) number to identify overlapping entries. 115 providers appear in both sources. After deduplication, the combined dataset contains 3,606 unique providers.

Provider credentials and specialties were verified against the CMS NPI Registry (NPPES) when NPI numbers were available. Population estimates are based on U.S. Census Bureau 2024 estimates.

This data represents certified and registered providers only. The actual number of practitioners offering ketamine therapy in the United States may be higher, as some providers administer ketamine without ASKP membership or Spravato certification (e.g., anesthesiologists providing off-label IV ketamine infusions).

2. National Overview

3,606 ketamine therapy providers across 51 states and DC

MetricCountPercentage
Total unique providers3,606100%
Spravato REMS-certified centers3,30291.6%
ASKP member clinics41911.6%
Listed in both registries1153.2%
Spravato-only (not ASKP)3,18788.4%
ASKP-only (not Spravato-certified)3048.4%
States with at least one provider51100% of states

The dominance of Spravato REMS-certified centers (91.6% of all providers) reflects the growth of the FDA-approved pathway since esketamine’s approval in March 2019. ASKP member clinics, which more commonly offer IV ketamine infusions and ketamine-assisted psychotherapy (KAP), represent a smaller but clinically significant segment of the market.

3. Providers by State

All 51 states and the District of Columbia have at least one registered ketamine therapy provider. The top 5 states by total provider count are California (336), Texas (325), Florida (218), New York (199), and Illinois (139).

# State Total Providers Spravato ASKP Per 1M Pop.
1 California 336 292 55 8.6
2 Texas 325 288 50 10.7
3 Florida 218 201 24 9.6
4 New York 199 188 22 10.2
5 Illinois 139 135 8 11.1
6 Ohio 119 112 10 10.1
7 Arizona 115 99 20 15.5
8 New Jersey 113 108 10 12.2
9 North Carolina 113 105 9 10.6
10 Virginia 102 96 9 11.7
11 Massachusetts 96 86 10 13.7
12 Utah 90 87 3 26.5
13 Tennessee 87 82 8 12.3
14 Washington 86 64 24 11.0
15 Maryland 86 84 5 13.9
16 Pennsylvania 81 76 9 6.3
17 Michigan 80 77 5 8.0
18 Indiana 72 67 7 10.4
19 Colorado 71 56 20 12.0
20 Kansas 68 67 4 23.4
21 Missouri 68 67 1 11.0
22 Connecticut 65 58 8 18.1
23 Kentucky 63 59 6 14.0
24 Georgia 62 58 6 5.6
25 Iowa 62 59 7 19.4
26 Oklahoma 59 56 3 14.4
27 Louisiana 57 55 2 12.4
28 Nebraska 55 54 2 27.5
29 Arkansas 53 52 3 17.1
30 Minnesota 47 44 8 8.2
31 Oregon 47 43 5 11.2
32 Nevada 42 35 8 13.1
33 Alabama 37 32 6 7.3
34 South Carolina 36 34 3 6.7
35 Wisconsin 34 30 5 5.8
36 Idaho 30 27 6 15.0
37 West Virginia 27 27 0 15.0
38 Mississippi 26 26 0 9.0
39 Montana 22 18 6 20.0
40 New Mexico 16 10 6 7.6
41 New Hampshire 16 15 1 11.4
42 Maine 14 13 1 10.0
43 Delaware 12 10 3 12.0
44 Rhode Island 12 11 1 10.9
45 Alaska 10 10 0 13.7
46 Vermont 9 6 3 13.8
47 South Dakota 9 9 0 9.9
48 Wyoming 6 3 3 10.3
49 North Dakota 5 4 1 6.4
50 Hawaii 5 4 1 3.6
51 District of Columbia 4 3 2 5.8

4. Clinic Density Per Capita

Adjusting for population reveals a different geographic picture. States with the highest per-capita provider density are not necessarily the most populous. Nebraska leads with 27.5 providers per million residents, followed by Utah (26.5) and Kansas (23.4).

National average density: 10.8 providers per million residents (based on estimated 2024 US population of 335 million)

# State Per 1M Residents Total Providers Population (est.)
1 Nebraska 27.5 55 2.0M
2 Utah 26.5 90 3.4M
3 Kansas 23.4 68 2.9M
4 Montana 20.0 22 1.1M
5 Iowa 19.4 62 3.2M
6 Connecticut 18.1 65 3.6M
7 Arkansas 17.1 53 3.1M
8 Arizona 15.5 115 7.4M
9 Idaho 15.0 30 2.0M
10 West Virginia 15.0 27 1.8M
11 Oklahoma 14.4 59 4.1M
12 Kentucky 14.0 63 4.5M
13 Maryland 13.9 86 6.2M
14 Vermont 13.8 9 0.7M
15 Massachusetts 13.7 96 7.0M

The lowest-density states are Hawaii (3.6 per 1M), suggesting that geographic isolation and market size limit provider availability. Patients in low-density states may need to travel to access ketamine therapy or consider telehealth-based oral ketamine programs.

5. Top Cities by Provider Count

Major metropolitan areas concentrate the most providers. New York City leads with 45 providers, followed by Houston (40) and San Antonio (30).

# City Total Providers Spravato ASKP
1 New York, NY 45 39 8
2 Houston, TX 40 34 7
3 San Antonio, TX 30 26 7
4 Omaha, NE 27 27 1
5 Austin, TX 25 17 9
6 Phoenix, AZ 21 20 3
7 Chicago, IL 20 19 2
8 Dallas, TX 20 18 2
9 Las Vegas, NV 19 16 3
10 San Diego, CA 17 15 4
11 Tampa, FL 17 16 2
12 Tulsa, OK 16 15 1
13 Tucson, AZ 16 15 1
14 Gilbert, AZ 15 11 5
15 Wichita, KS 15 15 0
16 Los Angeles, CA 14 12 3
17 Portland, OR 14 13 1
18 Sacramento, CA 14 13 1
19 Miami, FL 14 12 3
20 Nashville, TN 13 11 3

6. Provider Specialties

Of the 718 providers with NPI data available, the most common specialties are psychiatry, nurse practitioner (psychiatric), and anesthesiology. This reflects the multidisciplinary nature of ketamine therapy, which spans psychiatric, anesthesia, and primary care settings.

Specialty Count % of NPI-Verified
Psychiatry & Neurology, Psychiatry 183 25.5%
Nurse Practitioner, Psych/Mental Health 77 10.7%
Clinic/Center, Mental Health (Including Community Mental Health Center) 38 5.3%
Emergency Medicine 37 5.2%
Anesthesiology 33 4.6%
Nurse Anesthetist, Certified Registered 29 4.0%
Family Medicine 24 3.3%
Nurse Practitioner, Family 20 2.8%
Clinic/Center, Multi-Specialty 17 2.4%
Internal Medicine 14 1.9%

The presence of emergency medicine physicians (37) and family medicine practitioners (24) among ketamine providers indicates that ketamine therapy is not limited to psychiatric or anesthesia practices, though these remain the dominant specialties.

7. Data Source Overlap Analysis

The two primary data sources (Spravato REMS registry and ASKP directory) have limited overlap, indicating they capture distinct segments of the ketamine therapy market:

  • 3,187 providers (88.4%) appear only in the Spravato REMS registry — these are facilities certified to administer esketamine nasal spray but not ASKP members
  • 304 providers (8.4%) appear only in the ASKP directory — these typically focus on IV ketamine, IM ketamine, or KAP without Spravato certification
  • 115 providers (3.2%) appear in both sources — full-service ketamine clinics offering both Spravato and other ketamine modalities

The low overlap rate (3.2%) underscores that Spravato REMS centers and ASKP member clinics serve different market segments. Aggregating both sources is essential for a comprehensive picture of ketamine therapy availability in the United States.

8. How to Cite This Data

This data is published under a Creative Commons Attribution 4.0 (CC BY 4.0) license. You are free to share and adapt this data for any purpose, including commercial use, provided you give appropriate credit.

Suggested citation: DrugsRegistry.com. “Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis.” Published April 16, 2026. https://drugsregistry.com/ketamine-clinics-statistics/. Accessed [date].

For Wikipedia editors: This analysis provides verifiable, primary-source data on the number and distribution of ketamine therapy providers in the United States, compiled from two authoritative registries (Spravato REMS and ASKP). Individual data points can be independently verified against the source registries.

Data Sources

  1. Janssen Pharmaceuticals / U.S. Food and Drug Administration. Spravato REMS (Risk Evaluation and Mitigation Strategy) Treatment Center Registry. https://www.spravatorems.com/. Accessed April 2026.
  2. American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). Member Provider Directory. https://www.askp3.org/. Accessed April 2026.
  3. Centers for Medicare & Medicaid Services. National Plan and Provider Enumeration System (NPPES) NPI Registry. https://npiregistry.cms.hhs.gov/. Used for provider credential and specialty verification.
  4. U.S. Census Bureau. State Population Estimates, 2024. Used for per-capita density calculations.